Transaction DateRecipientSharesTypePriceValue
9th June 2020Dietrich A Stephan1,275Open or private purchase$7.73$9,860.72
21st May 2020Dietrich A Stephan1,250Open or private purchase$8.09$10,111.00
30th April 2020Dov A Md Goldstein10,000Open or private purchase$6.00$60,000.00
30th April 2020Eric I Richman2,500Open or private purchase$6.00$15,000.00
30th April 2020Eric I Richman8,333Open or private purchase$6.00$49,998.00
30th April 2020Samuel Backenroth1,000Open or private purchase$6.00$6,000.00
30th April 2020Dietrich A Stephan10,000Open or private purchase$6.00$60,000.00
28th February 2020Dov A Md Goldstein7,500Grant/award etc.$0.00
28th February 2020Eric I Richman7,500Grant/award etc.$0.00
12th July 2019Dietrich A Stephan2,547,639Grant/award etc.$0.00
Ohr Pharmaceutical
Ohr Pharmaceutical logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008.


Ticker: OHRP
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1173281
Employees: 3
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals